KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC – Trademark Portfolio
Entity Type: 03
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. Currently, 14 trademarks are registered. Notable registered marks include ALTACE, CORGARD, CORZIDE, LEVOXYL, and SKELAXIN. The owner is based in New York, NY.
66 Hudson Boulevard East
New York, NY 100012192
Showing of trademarks Trademarks
Trademark Classifications
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC have?
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC has 15 U.S. trademarks filed with the USPTO. Of these, 14 registered, 1 cancelled.
What trademark classes does KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC file in?
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC's most well-known trademarks?
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC's registered trademark portfolio includes well-known marks such as ALTACE, CORGARD, CORZIDE, LEVOXYL, and SKELAXIN. These are among 14 currently registered trademarks in the portfolio.
What is KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC's trademark registration success rate?
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, LLC has a 93% trademark registration rate, with 14 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.